Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma

Autor: Michael J. Harvey, Yi Zhong, Eric Morris, Jacob N. Beverage, Robert S. Epstein, Anita J. Chawla

Publikováno v: PLoS ONE, Vol 17, Iss 1 (2022)

Subcutaneous (SC) administration of rituximab provides an opportunity for reduced patient treatment burden and increased healthcare efficiencies as an alternative to intravenous (IV) rituximab. There is minimal evidence comparing costs associated wit

Externí odkaz: https://doaj.org/article/4d8465c0fcd94518be20434a00262695

Practice Patterns and Treatment Challenges in Acute Postoperative Pain Management: A Survey of Practicing Physicians

Autor: Tong J. Gan, Robert S. Epstein, Megan L. Leone-Perkins, Tehseen Salimi, Sheikh Usman Iqbal, Peter G. Whang

Publikováno v: Pain and Therapy, Vol 7, Iss 2, Pp 205-216 (2018)

Abstract Introduction The management of acute postoperative pain remains a significant challenge for physicians. Poorly controlled postoperative pain is associated with poorer overall outcomes. Methods Between April and May 2017, physicians from an o

Externí odkaz: https://doaj.org/article/0149bbb318b943ef8b732cc2ba23e89c

Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes

Autor: Amer M. Zeidan, Namita Joshi, Hrishikesh Kale, Wei-Jhih Wang, Shelby Corman, Tehseen Salimi, Robert S. Epstein

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:670-679

Previous analyses using the SEER-Medicare database have reported substantial underutilization of hypomethylating agents (HMAs) among patients with higher-risk myelodysplastic syndromes (MDS), and an association between poor HMA persistence and high e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0385d789603c375d048eeab05abd5a6d
https://doi.org/10.1016/j.clml.2022.04.016

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

Autor: Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-Josef Klümpen, Heung-Moon Chang, Li-Tzong Chen, Josep Tabernero, Do-Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Robert S. Epstein, Abdel-Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John A. Bridgewater

Publikováno v: New England Journal of Medicine, 388(3), 228-239. Massachussetts Medical Society
Goyal, L, Meric-Bernstam, F, Hollebecque, A, Valle, J W, Morizane, C, Karasic, T B, Abrams, T A, Furuse, J, Kelley, R K, Cassier, P A, Klümpen, H-J, Chang, H-M, Chen, L-T, Tabernero, J, Oh, D-Y, Mahipal, A, Moehler, M, Mitchell, E P, Komatsu, Y, Masuda, K, Ahn, D, Epstein, R S, Halim, A-B, Fu, Y, Salimi, T, Wacheck, V, He, Y, Liu, M, Benhadji, K A & Bridgewater, J A 2023, ' Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma ', New England Journal of Medicine, vol. 388, no. 3, pp. 228-239 . https://doi.org/10.1056/NEJMoa2206834

Background: Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afcafd318735846a74b18ed60752c0b
https://research.vumc.nl/en/publications/cd4cc245-ebdb-4ee6-adae-ae845072be13

Real-world genomic testing, treatment, and outcomes in patients with cholangiocarcinoma with FGFR2 fusions/rearrangements

Autor: Mitesh J. Borad, Therese Conner, LiHong He, Reza Kazerooni, Tehseen Salimi, Robert S. Epstein

Publikováno v: Journal of Clinical Oncology. 40:e16168-e16168

e16168 Background: Several fibroblast growth factor receptor (FGFR) inhibitors have been recently approved or are in development for the treatment of cholangiocarcinoma (CCA) with FGFR2 fusions/rearrangements (f/r), such as the ATP-competitive inhibi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8903bd424727838637714df361484e8
https://doi.org/10.1200/jco.2022.40.16_suppl.e16168